Latest NewsYesterday NewsQuote ListTopic ListQuote List

辉瑞：正与华海药业积极推进 Paxlovid 本地化生产，确保中国市场充足供应

USHK News
2023.01.11 02:09
金十数据 1 月 11 日讯，对于 Paxlovid 在 2022 年国家医保目录谈判中出局，辉瑞 1 月 11 日回应澎湃新闻，虽然 Paxlovid 未能纳入国家医保目录，辉瑞仍将一如既往地配合政府和其他相关合作方，确保 Paxlovid 在中国市场的充足供应，以持续满足中国患者的新冠治疗需求。本地化生产方面，辉瑞表示目前公司和华海药业正在积极推进 Paxlovid 地产化项目的各项工作，以保障 Paxlovid 在中国市场的充足供应，持续满足中国患者的新冠治疗需求。
Source: USHK News The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.